A phase II trial of m-AMSA in patients with small-cell lung cancer.

R. B. Natale, R. J. Gralla, R. E. Wittes

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.

Original languageEnglish (US)
Pages (from-to)393-395
Number of pages3
JournalCancer clinical trials
Volume4
Issue number4
StatePublished - Dec 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'A phase II trial of m-AMSA in patients with small-cell lung cancer.'. Together they form a unique fingerprint.

Cite this